Pearl Therapeutics Receives $69,000,000 Series C Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f850f32f-a55d-4ec7-9043-d6762dae0c23&Preview=1 -
Date
10/19/2010 -
Company Name
Pearl Therapeutics -
Mailing Address
200 Saginaw Drive Redwood City, CA 94063 -
Company Description
Pearl Therapeutics is focused on developing a pipeline of novel and
superior products for chronic respiratory disorders, providing patients
with advanced therapeutic options in familiar and well accepted dosage
forms. The company has licensed advanced particle technology from Nektar
Therapeutics (Nasdaq: NKTR) for developing a series of products in selected
therapeutic fields. -
Website
http://www.pearltherapeutics.com -
Transaction Type
Venture Equity -
Transaction Amount
$69,000,000 -
Transaction Round
Series C -
Proceeds Purposes
The capital raised in this Series C financing will enable Pearl to complete the entire Phase 2b program for its lead product. -
M&A Terms
-
Venture Investor
Vatera Healthcare Partners -
Venture Investor
Clarus Ventures -
Venture Investor
New Leaf Venture Partners -
Venture Investor
5AM Ventures
